$
36.630
+0.39(1.076%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
37.000
Open
36.140
VWAP
36.14
Vol
1.09M
Mkt Cap
4.73B
Low
35.460
Amount
39.34M
EV/EBITDA(TTM)
--
Total Shares
108.80M
EV
3.05B
EV/OCF(TTM)
--
P/S(TTM)
--
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Show More
6 Analyst Rating
up Image
157.30% Upside
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 94.25 USD with a low forecast of 65.00 USD and a high forecast of 137.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
157.30% Upside
Current: 36.630
sliders
Low
65.00
Averages
94.25
High
137.00
Mizuho
Salim Syed
Outperform
maintain
2025-06-21
Reason
Cantor Fitzgerald
Carter Gould
Buy
Initiates
n/a
2025-04-22
Reason
Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte with an Overweight rating.
Needham
Joseph Stringer
Strong Buy
Reiterates
$90
2025-04-08
Reason
Needham
Joseph Stringer
Strong Buy
Maintains
$140 → $90
2025-04-01
Reason
B of A Securities
Jason Gerberry
Strong Buy
Maintains
$157 → $137
2025-04-01
Reason
Goldman Sachs
Chris Shibutani
Strong Buy
Maintains
$138 → $100
2025-04-01
Reason

Valuation Metrics

The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.37, compared to its 5-year average forward P/E of -12.77. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.77
Current PE
-7.37
Overvalued PE
-8.45
Undervalued PE
-17.08

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.46
Current EV/EBITDA
-4.61
Overvalued EV/EBITDA
-5.98
Undervalued EV/EBITDA
-16.95

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
699.87
Current PS
0.00
Overvalued PS
1848.88
Undervalued PS
-449.13

Financials

Annual
Quarterly
FY2025Q1
YoY :
+58.11%
-180.79M
Operating Profit
FY2025Q1
YoY :
+48.09%
-140.72M
Net Income after Tax
FY2025Q1
YoY :
+22.35%
-1.04
EPS - Diluted
FY2025Q1
YoY :
+12.75%
-193.03M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.8M
USD
5
6-9
Months
9.0M
USD
12
0-12
Months
20.5M
USD
14
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.4M
Volume
3
6-9
Months
1.3M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
7
6.2M
Volume
Months
6-9
7
3.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
24.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PCVX News & Events

Events Timeline

2025-05-15 (ET)
2025-05-15
12:59:01
FDA head says vaccine framework being prepared
select
2025-05-07 (ET)
2025-05-07
16:09:02
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)
select
2025-05-01 (ET)
2025-05-01
08:13:21
Vaxcyte appoints Brandicourt to board of directors
select
Sign Up For More Events

News

6.5
06-05NASDAQ.COM
The Math Shows ESML Can Go To $48
2.0
05-06NASDAQ.COM
Oversold Conditions For Vaxcyte (PCVX)
5.0
05-06SeekingAlpha
Vinay Prasad to head FDA division regulating vaccines
Sign Up For More News

FAQ

arrow icon

What is Vaxcyte Inc (PCVX) stock price today?

The current price of PCVX is 36.63 USD — it has increased 1.08 % in the last trading day.

arrow icon

What is Vaxcyte Inc (PCVX)'s business?

arrow icon

What is the price predicton of PCVX Stock?

arrow icon

What is Vaxcyte Inc (PCVX)'s revenue for the last quarter?

arrow icon

What is Vaxcyte Inc (PCVX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Vaxcyte Inc (PCVX)'s fundamentals?

arrow icon

How many employees does Vaxcyte Inc (PCVX). have?

arrow icon

What is Vaxcyte Inc (PCVX) market cap?